Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 833 results for "merck co"

Sun Pharma shares end nearly 2 pc up on Merck licensing pact

Shares of Sun Pharmaceutical Industries today ended nearly 2 per cent higher after the company entered into a licensing agreement with Merck & Co Inc for using investigational therapeutic antibody candidate, tildrakizumab for treatment of plaque psoriasis. Business Standard, 1 hour ago
Sun Pharma shares up 3% on Merck licensing pact Hindu Business Line, 6 hours ago

65 images for merck co

KansasCity.com, 1 week ago
CNBC, 1 week ago
Pueblo Chieftain Online, 1 week ago
Orlando Sentinel, 3 weeks ago
Sify, 7 hours ago
Dividend.com, 3 weeks ago
Jutia Group, 3 weeks ago
BioSpace, 6 days ago
BioSpace, 6 days ago
Pharma Letter, 3 weeks ago
Reuters

Sun Pharma and Merck & Co in agreement

Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80 million Merck & Co, known as MSD outside the US and Canada, and Sun Pharmaceutical Industries through ...
 Express Pharma8 hours ago Sun Pharma gains 2% on pact with Merck & Co for Tildrakizumab  Business Standard9 hours ago Sun-Merck tie-up on psorasis drug  Hindu Business Line19 hours ago Sun Pharma, Merck enter into pact for Tildrakizumab  Economic Times22 hours ago
[x]  

Merck Reports Progress In Type-2 Diabetes Drug Trials

Merck yesterday, released positive Phase III results for its type-2 diabetes drug, pushing the company closer to filing for approval in Japan. Meanwhile, the company has licensed its psoriasis drug to India-based Sun Pharmaceuticals Page 1 of 2 ...
 Bidness Etc2 hours ago Merck Announces Positive Phase III Results For Odanacatib; Drug's Safety Profile Raises Red Flags  Bidness Etc2 days ago Merck's odanacatib succeeds in Ph III osteoporosis trial  Pharma Letter1 day ago Merck & Co.'s osteoporosis drug odanacatib hits main goal in Phase III study  FirstWord Pharma2 days ago

Merck Posts Positive Data on Osteoporosis Drug Odanacatib

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight ...
 Yahoo! Finance15 hours ago
[x]  

Merck KGaA seeks partner for immuno-oncology drug by year-end

* Competitive process to find partner for anti-PD-L1 drug * Experimental drug in hot new area for cancer research * Merck plans increased investment in biosimilar drugs * Pharma head Oschmann appointed deputy CEO (Adds details on drug, wraps in ...
 Sharenet3 hours ago MERCK KGAA : In Talks With Potential Partners to Develop Immuno-Oncology Drug  4 Traders3 hours ago UPDATE 1-Merck KGaA seeks partner for immuno-oncology drug by year-end  Reuters UK3 hours ago
[x]  
Business Today India

Sun Pharma gains after inking pact with Merck

Sun Pharmaceutical Industries announced that it has entered into an exclusive worldwide licensing agreement with the US-based Merck & Co (known as MSD outside the US and Canada) for the latter's investigational therapeutic antibody candidate tildrakizumab, ...
 Business Standard9 hours ago Sun Pharma in focus on inking pact with Merck  Business Standard9 hours ago Sun Pharma to acquire skin ailment drug rights from Merck  DNA India11 hours ago Sun Pharma To Buy Global Rights To Merck's Product Candidate Tildrakizumab  RTTNews.com1 day ago
[x]  
Sify

Sun Pharma Gains on Merck Licensing Pact

Sun Pharmaceutical Industries gained 2 per cent after Merck & Co Inc said it had licensed its experimental psoriasis drug to Sun. This is the first instance of an Indian company taking global rights for a novel drug, traders say. The deal ...
 NDTV Profit8 hours ago Sun Pharma licenses Merck psoriasis drug for $80M  Investor's Business Daily22 hours ago Sun Pharma gains; becomes first to license drug from innovator  Yahoo! Malaysia8 hours ago Sun Pharma Licenses Merck & Co. Phase III Psoriasis Candidate in $80M+ Accord  Genetic Engineering News20 hours ago
[x]  

Merck (MRK) Trading Near $60.56 Resistance Level

Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) was selected by MarketIntelligenceCenter.comaEUR(TM)s trade-picking algorithms today after trading between $59.28 and $60.06 on Tuesday before closing at $59.99. A diagonal ...
 Individual.com18 hours ago Merck (MRK) Showing Resistance Near $60.16  Individual.com1 day ago

Sun Pharma, Merck ink pact for Tildrakizumab

Comment · print · T T T+· T- TOPICS Sun Pharmaceutical Industries and Merck & Co (known as MSD outside the U.S. and Canada) through their subsidiaries entered an exclusive worldwide licensing agreement for Merck's investigational ...
 The Hindu19 hours ago

OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary

Former Senior Patent Counsel at Merck & Co., Inc. to Oversee Global Legal Strategy SAN DIEGO--(BUSINESS WIRE)-- OncoSec Medical Inc. (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela ...
 CNBC1 day ago OncoSec Medical Inc. Names Sheela Mohan-Peterson As GC  Today's General Counsel14 hours ago OncoSec Medical Brings Aboard Its First GC  Corporate Counsel19 hours ago OncoSec Medical Expands Legal Team Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary  PharmiWeb1 day ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less